Amano T, Takeda T, Yano H, Tamura T
Pharmaceutical Research Center, Kyowa Hakko Kogyo Co Ltd, 1188 Shimotogari, Sunto-Gun, Shizuoka, Japan.
Br J Dermatol. 2007 May;156(5):906-12. doi: 10.1111/j.1365-2133.2007.07796.x. Epub 2007 Mar 13.
The skin barrier function in patients with atopic dermatitis is disrupted and prolonged topical steroid therapy produces epidermal barrier disturbance. Olopatadine hydrochloride (olopatadine; Allelock; Kyowa Hakko Kogyo Co., Ltd, Shizuoka, Japan) is an antiallergic drug with histamine H(1) receptor antagonistic action. This drug alleviates skin inflammation and decreases the number of scratching episodes in a murine model of chronic contact dermatitis.
To investigate the effects of olopatadine and a steroid on the recovery of skin barrier function after barrier disruption in mice.
The skin barrier of the ears of mice was disrupted by tape stripping. The recovery of skin barrier function was monitored by measurement of transepidermal water loss (TEWL) after barrier disruption. Epidermal hyperplasia was induced by repeated tape stripping for 7 days. Olopatadine was administered orally once daily from 3 days before the first barrier disruption. Betamethasone 17-valerate (betamethasone) was applied topically once daily from 3 days before barrier disruption.
Tape stripping led to a significant increase in TEWL. TEWL decreased with time after tape stripping and the skin barrier function recovered by over 60% within 9 h after tape stripping. The recovery of skin barrier in olopatadine-treated mice was significantly accelerated, compared with that in vehicle-treated mice. In contrast, the skin barrier recovery in mice treated with topical betamethasone was significantly delayed, compared with that in vehicle-treated mice. Combined treatment with olopatadine and betamethasone ameliorated the delay in barrier recovery induced by topical treatment with betamethasone. In addition, olopatadine significantly prevented the increase in epidermal thickness induced by prolonged barrier disruption.
These results suggest that systemic administration of olopatadine accelerates the recovery of skin barrier function and ameliorates the adverse effects of topical steroids on skin barrier recovery.
特应性皮炎患者的皮肤屏障功能受损，长期局部使用类固醇疗法会导致表皮屏障紊乱。盐酸奥洛他定（奥洛他定；Allelock；日本静冈协和发酵工业株式会社）是一种具有组胺H(1)受体拮抗作用的抗过敏药物。该药物可减轻皮肤炎症，并减少慢性接触性皮炎小鼠模型中的搔抓次数。
研究奥洛他定和类固醇对小鼠屏障破坏后皮肤屏障功能恢复的影响。
通过胶带剥离破坏小鼠耳部的皮肤屏障。屏障破坏后，通过测量经表皮水分流失（TEWL）来监测皮肤屏障功能的恢复情况。通过连续7天重复胶带剥离诱导表皮增生。从首次屏障破坏前3天开始，每天口服一次奥洛他定。从屏障破坏前3天开始，每天局部应用一次17-戊酸倍他米松（倍他米松）。
胶带剥离导致TEWL显著增加。胶带剥离后TEWL随时间下降，皮肤屏障功能在胶带剥离后9小时内恢复超过60%。与赋形剂处理的小鼠相比，奥洛他定处理的小鼠皮肤屏障的恢复明显加快。相比之下，局部应用倍他米松处理的小鼠皮肤屏障恢复明显延迟。奥洛他定和倍他米松联合治疗改善了局部应用倍他米松引起的屏障恢复延迟。此外，奥洛他定显著预防了长期屏障破坏引起的表皮厚度增加。
这些结果表明，全身给予奥洛他定可加速皮肤屏障功能的恢复，并改善局部类固醇对皮肤屏障恢复的不良影响。
